Aims: The Ross operation is the operation of choice for children who require aortic valve replacement (AVR) and may also provide a good option in selected adult patients. Although the autograft does not require anticoagulation and has a superior haemodynamic profile, concern regarding autograft and allograft longevity has risen. In this light, we report the 13-year results of our prospective autograft cohort study. Methods and results: Between 1988 and 2005, 146 consecutive patients underwent AVR with a pulmonary autograft at Erasmus Medical Center Rotterdam. Mean age was 22 years (SD 13; range 4 months-52 years), 66% were male. Hospital mortality was 2.7% (N = 4); during follow-up four more patients died. Thirteen-year survival was 94 ± 2%. Over time, 22 patients required autograft reoperation for progressive neo-aortic root dilatation. In addition, eight patients required allograft reoperation. Freedom from autograft reoperation at 13 years was 69 ± 7%. Freedom from allograft reoperation for structural failure at 13 years was 87 ± 5%. Risk factors for autograft reoperation were previous AVR and adult patient age. Conclusion: Although survival of the Rotterdam autograft cohort is excellent, over time a worrisome increase in reoperation rate is observed. Given the progressive autograft dilatation, careful follow-up of these patients is warranted in the second decade after operation.

Additional Metadata
Keywords Autograft dilatation, Prospective study, Reoperation, Ross operation, Survival
Persistent URL,
Journal European Heart Journal
Klieverik, L.M.A, Takkenberg, J.J.M, Bekkers, J.A, Roos-Hesselink, J.W, Witsenburg, M, & Bogers, A.J.J.C. (2007). The Ross operation: A Trojan horse?. In European Heart Journal (Vol. 28, pp. 1993–2000). doi:10.1093/eurheartj/ehl550